Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma ☆Thejus Jayakrishnan, Santhosh Sadashiv, Rodney E. Wegner et al.|Hematology/Oncology and Stem Cell Therapy|2020Cited by 19
Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphomaAntoine Hollebecque, Monica Mita, Sarit Assouline et al.|Molecular Cancer Therapeutics|2019Cited by 2